Skip to main content
. 2020 May 7;15(5):e0232240. doi: 10.1371/journal.pone.0232240

Fig 2.

Fig 2

Tornado diagram of the one-way sensitivity analysis of the Incremental Cost-Effectiveness Ratio (ICER) of RAM over chemotherapy in all patients in the mainland China (A) and the Beijing city (B). PD, progressed disease; PFS, Progressed-free disease; RAM, ramucirumab.